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Background: Children with critical illness have increased intestinal permeabil-
ity and a period of immunoparalysis, mediated by elevated circulating endotoxin. 
Whether children with less severe infections have similar changes is uncertain.
Methods: We conducted a proof-of-concept pilot study, enrolling children 
6–59 months of age hospitalized for noncritical infections (cases, n = 11) 
and noninfected controls (n = 19). Intestinal permeability was measured 
by lactulose–mannitol recovery. Plasma endotoxin, blood monocyte and 
neutrophil immunophenotypes and cytokine elaboration following 24-hour 
whole-blood culture with antigens targeting distinct innate pathogen recog-
nition receptor signaling pathways were evaluated.
Results: Cases had higher intestinal permeability and plasma endotoxin lev-
els than controls. Among cases versus controls, fewer monocytes expressed 
human leukocyte antigen DR isotype (HLA-DR) (87.1% vs. 96.4%, P = 
0.001), and more expressed CD64 (99.6% vs. 97.6%, P = 0.041). Following 
zymosan stimulation of whole blood, cases versus controls produced less 
interleukin 1 beta (IL-1β) (median 1101 vs. 2604 pg/mL, P = 0.048) and tumor 
necrosis factor alpha (TNF-α) (2342 vs. 5130 pg/mL, P = 0.031). Children 
with higher (≥0.1 endotoxin unit (EU)/mL) versus lower (<0.1 EU/mL) cir-
culating endotoxin had fewer monocytes expressing CD86 (69.8% vs. 92.4%, 
P = 0.003) and less expression of CD64 following 24-hour zymosan stimu-
lation (median fluorescence intensity (MFI) 1514 vs. 2196, P = 0.022).
Conclusions: Children hospitalized with noncritical infections had increased 
intestinal permeability, endotoxemia and altered monocyte phenotype and 
function. Collectively, these changes are typical of immunoparalysis seen in 
children with critical illness and may increase the risk of subsequent infections.
Key Words: child, gut permeability, innate immunity, monocytes, lipopoly-
saccharide
(Pediatr Infect Dis J 2019;38:741–748)
Children with critical illness, such as sepsis, subsequently have a period of reversible immune dysfunction.1 This state of 
immunoparalysis is characterized by reduced monocyte function, 
including lower human leukocyte antigen DR isotype (HLA-DR) 
expression and reduced tumor necrosis factor alpha (TNF-α) pro-
duction upon restimulation, increased risk of secondary infections 
and elevated mortality.1 A potent mediator of this process is lipopol-
ysaccharide (LPS),2 also called endotoxin, a highly immunogenic 
component of the outer membrane of Gram-negative bacteria. “LPS 
tolerance” can reduce the proinflammatory response to a subsequent 
immune challenge3 through alterations in metabolic and epigenetic 
pathways that drive innate immune cell reprograming.4
Elevated circulating levels of LPS (endotoxemia) are detect-
able even in Gram-positive infections,5 and noninfectious condi-
tions like trauma,6 obesity,7 severe autism8 and cardiac arrest.9 
Thus, endotoxaemia is not necessarily an indicator of infection. 
The source of circulating LPS remains uncertain, but the intestinal 
tract represents a plausible site because it contains a large number 
of commensal Gram-negative bacteria as part of the gut microbi-
ota.10 The gut is fundamentally altered during critical illness, with 
overgrowth of bacterial species in the upper intestine, dysbiosis of 
the microbiota in the lower intestine and loss of gut barrier func-
tion.11 With increased intestinal permeability, bacteria and micro-
bial products can translocate to mesenteric lymph nodes and to the 
bloodstream, exposing immune cells directly to bacterial antigens, 
including LPS. Whether this process drives immunoparalysis and 
increased susceptibility to subsequent infections in critical illness 
remains uncertain, but has been widely proposed by clinical stud-
ies5,6 and is supported by data from animal models.12,13
To date, immunoparalysis has been predominantly investigated 
in critical illness; however, it is possible that immune cell phenotype 
and function can also be modulated in the context of less severe infec-
tions. Epidemiologic data suggest that an episode of infectious ill-
ness increases the risk of subsequent infections of a child, and it has 
been suggested that immunoparalysis may be one mechanism under-
lying this observation.14 Furthermore, intestinal permeability can be 
increased during systemic,15 intestinal16,17 and nonintestinal infec-
tions.18 Given that the immune response to intravenously administered 
endotoxin can itself increase intestinal permeability in healthy adult 
volunteers,19–23 a reinforcing cycle may occur, with potential to affect 
both subsequent immune responses and intestinal permeability.
We therefore set out to investigate first whether children 
with noncritical infections have evidence of increased intestinal 
permeability, endotoxemia and innate immune dysfunction similar 
to the immunoparalysis of critical illness. Second, we investigated 
whether endotoxemia was associated with immune dysfunction by 
comparing innate immune cell phenotype and function between 
groups of children stratified by their circulating LPS levels, inde-
pendently of their infection status.
MATERIALS AND METHODS
Ethics
The study received ethical approval from UK National 
Health Service Health Research Authority Research Ethics Service 
through the Hampstead Research Ethics Committee (16/LO/2213). 
Participants were recruited following written informed consent 
from their parent or guardian.
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Study Cohort
Children 6–59 months of age were recruited from the Royal 
London Hospital between March and June 2017. Cases were 
recruited from children hospitalized for noncritical infections, 
which we defined as having a documented fever above 38°C and 
C-reactive protein (CRP), if measured for clinical management, 
>10 mg/L, with no end-organ dysfunction. We chose broad crite-
ria to identify children with a systemic febrile and inflammatory 
response to infection, regardless of the specific etiology, to reflect 
the wide range of infectious causes and diagnostic uncertainty 
when treating children with fever. Controls were defined as children 
who were either hospitalized or attending the day-care unit, were 
not acutely unwell, had no fever in the past week and, if measured, 
had CRP < 10 mg/L. Controls were therefore free of symptomatic 
infection (the main focus of this study), but did have noninfectious 
conditions requiring a day visit to hospital. The collection of urine 
and blood was carried out before any planned day-case procedure.
Cases and controls were excluded if they had gastrointes-
tinal symptoms, defined as persistent vomiting or passage of 3 or 
more watery or loose stools in the previous 24 hours. Any children 
with known or suspected chronic inflammatory or gastrointestinal 
disease were excluded.
Collection of Blood
Up to 5 mL of blood was collected from all participants 
by venepuncture into a glass sodium heparin tube (BD, Franklin 
Lakes, NJ). The duration of infectious symptoms before hospital 
admission varied at the time of sampling and was not standard-
ized across participants. Although endotoxin concentrations are not 
reported by the manufacturer, random sampling of blood collec-
tion tubes after addition of 3 mL of endotoxin-free water revealed 
LPS concentrations <0.01 EU/mL. All other laboratory equipment 
was certified endotoxin free. Whole blood was used for assays as 
described below, then the remaining sample was centrifuged at 
1500g for 15 minutes to obtain plasma, which was stored at −80°C.
Immunophenotyping of Innate Immune Cells
We focused on innate immune cell phenotype and func-
tion, which are known to be impaired following sepsis24 and adapt 
to exposure to LPS and other stimuli.25 Our main read-outs were 
monocyte subpopulations, which are perturbed by systemic inflam-
mation,26 and markers of monocyte antigen presenting capacity 
(HLA-DR); T-cell costimulation (CD86) and LPS responsiveness 
[Toll-like receptor (TLR)4, the LPS receptor]. We also assayed 
CD64, a high-affinity FcγRI membrane glycoprotein that mediates 
endocytosis, phagocytosis, antibody-dependent cellular toxicity, 
cytokine release and superoxide generation27; it is raised in both 
febrile viral and bacterial infections,28 and lower expression in the 
context of infections has been associated with increased mortality.29
One hundred microliters of whole blood was stained for 
30 minutes with fluorochrome-conjugated antibodies (CD14–PE; 
CD16–Pacific Blue; HLA-DR–APC/Fire; CD64–FITC; CD86–
Brilliant Violet 605; TLR-4–APC and CD66a/c/e–PerCP-Cy5.5; 
all from Biolegend, San Diego, CA), following red-cell lysis (FACS 
Lysis Buffer, BD Biosciences, Franklin Lakes, NJ ). The gating strat-
egy used for identifying cell types and surface marker expression is 
shown in Fig. 1; Supplementary Digital Content 1, http://links.lww.
com/INF/D447. Briefly, total monocytes were selected as the CD14+ 
CD66a/c/e-negative population and subtypes identified by their 
CD14 and CD16 expression as classical (CD14++ CD16−), intermedi-
ate (CD14++ CD16+) and nonclassical (CD14+ CD16++) monocytes.30 
Neutrophils were identified as CD66a/c/e+ CD16+ cells.
Fluorescence-minus-one controls were used to set gating 
parameters. Compensation was undertaken with Ultracomp beads 
(eBioscience, San Diego, CA). Samples were run in duplicate on an 
LSR II (BD Biosciences) machine using BD FACSDiva software and 
analyzed using FlowJo v.10.2 software (FlowJo LLC, Ashland, OR).
Twenty-four-hour Whole Blood Stimulation
Whole blood was diluted 6-fold using RPMI with 1% added 
penicillin–streptomycin, then 1 mL was cultured for 24 hours at 
37°C with 5% CO
2
 in 24-well plates, stimulated in duplicate with 
0.5 endotoxin unit (EU)/mL of LPS and 0.5 µg/mL of zymosan 
(both Sigma-Aldrich, St Louis, MO), or RPMI/1% penicillin–
streptomycin without stimulant (control). After 24 hours, cells 
were analyzed by flow cytometry as described above, and culture 
supernatants were stored at −80°C for subsequent quantification of 
cytokines.
Measurement of Cytokines
Plasma and cell culture supernatant cytokines were meas-
ured in duplicate using commercial ELISA kits following manufac-
turer’s instructions: interleukin 1 beta (IL-1β) and TNF-α (Duoset; 
R&D Systems, Minneapolis, MN, Golbal headquarters in USA as 
per comment in the questions), and IL-6 (OptEIA ELISA Kit II; 
BD Biosciences).
Measurement of Endotoxin
Endotoxin concentrations were measured in plasma using 
a limulus amebocyte lysate assay (Pyrochrome kit; Associates of 
Cape Cod, Falmouth, MA) following the manufacturer’s instruc-
tions. Plasma was first diluted 1:10 with endotoxin-free water and 
then heated to 70°C for 30 minutes. The test was read using the 
kinetic method on a BioTek Synergy HT  (Winooski, VT) plate 
reader. Detection limits were 0.01 EU/mL in undiluted plasma. 
Samples were analyzed in triplicate with the mean taken.
Lactulose–Mannitol Assay
A lactulose–mannitol test was conducted on cases and con-
trols as previously described.31 Briefly, a solution of 250 mg/mL lact-
ulose and 50 mg/mL mannitol was given orally at a dose of 2 mL/kg 
up to a maximum of 20 mL. Children were fasted for at least 30 min-
utes and all urine was collected for 2 hours following administration 
of the solution. Aliquots of urine were stored at −80°C until analysis. 
Urinary lactulose and mannitol concentrations were measured using 
liquid chromatography-mass spectrometry, with a raffinose internal 
control. Each urine sample was analyzed twice and the mean value 
was used. A final lactulose:mannitol ratio (LMR) was calculated, 
using the recovery percentages of the lactulose and mannitol.
Sample Size and Statistics
This was a pilot proof-of-concept study. We aimed to enroll 
as many cases and controls as possible between March 1, 2017 
and June 1, 2017. Analysis was undertaken once all samples were 
collected and processed, using SPSS version 23.0 (IBM Corp, 
Armonk, NY) and Graphpad Prism v7.03 (GraphPad Software, San 
Diego, CA). Continuous variables were compared between groups 
using Mann-Whitney U tests, proportions were compared using 
Fisher Exact tests, and correlations were tested using Spearman 
rank correlation coefficients.
RESULTS
Thirty patients were recruited (11 cases, 19 controls), with 
baseline characteristics shown in Table 1. There were no signifi-
cant differences between cases and controls in age, weight, or 
weight-for-age Z-scores. Among cases, children were diagnosed 
with lower respiratory tract infection (n = 4), skin abscesses 
(n = 3), urinary tract infection (treated as an ascending infection 
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because of the fevers as per the national institute for health and 
care excellence guidelines; n = 2), osteomyelitis (n = 1) and sepsis 
with no source identified (n = 1). Among the noninfected controls, 
the majority (n = 13) were admitted for elective minor surgical 
day-case procedures including accessory digit removal, circumci-
sion and dental procedures; others were admitted to the day-care 
unit for blood tests due to thalassemia (n = 5), or for consideration 
of a blood transfusion for sickle cell disease (n = 1). Due to dif-
ficulty sampling, not passing urine, or contamination of urine with 
feces, there were some missing samples, as shown in Figure 1.
CASES VERSUS CONTROLS
Intestinal Permeability and Circulating Endotoxin
Plasma endotoxin concentrations were significantly higher 
in cases compared with controls (median 0.24 [interquartile range 
(IQR): 0.02, 0.54] vs. 0.02 (IQR: 0.01, 0.10) EU/mL, respec-
tively; P = 0.028; Fig. 2A). Cases compared with controls also had 
increased intestinal permeability as measured by the LMR [median 
0.09 (IQR: 0.03, 0.19) vs. 0.03 (IQR: 0.02, 0.09), respectively; 
P = 0.042; Fig. 2B]. This was due to both a decrease in mannitol 
recovery and an increase in lactulose recovery among cases (data 
not shown). There was a weak positive correlation between intesti-
nal permeability and circulating endotoxin concentrations (Spear-
man coefficient r = 0.38, P = 0.086).
Monocyte and Neutrophil Phenotype
There were no significant differences between the ratios of 
monocytes to lymphocytes between cases and controls (Table 1). 
Examining the peripheral blood monocyte population as a whole 
(CD66a/c/e− CD14+ cells), cases compared with controls had a sig-
nificantly lower percentage expressing HLA-DR (median 87.1% vs. 
96.4%; P = 0.001), and a higher percentage expressing CD64 (median 
99.6% vs. 97.6%; P = 0.041, Fig. 3); there was no significant differ-
ence in the percentage of monocytes expressing CD86 or TLR4.
Among the monocyte subpopulations, there were no sig-
nificant differences between cases and controls in proportions of 
TABLE 1. Summary of Participants
Cases  
(N = 11)
Controls  
(N = 19)
P Value  
(Cases vs.  
Controls)
Age, mo; median (range) 25 (6, 57) 31 (9, 52) 0.42*
Male, n (%) 7 (63.6) 12 (63.1) 0.45†
Weight, kg; median (range) 12.0 (9.1, 16.2) 13.4 (6.3, 27.0) 0.49*
Weight-for-age Z-score; median (range) −0.15 (−0.77, 1.85) −0.32 (−2.7, 3.2) 0.31*
Lymphocyte: monocyte ratio in whole blood; Median 
(range)
31.3 (7.4, 209) 21.2 (8.3, 67.7) 0.31*
CRP, mg/L; median (range)‡ 109 (22, 236) — —
White cell count × 109/L; median (range)‡ 16.3 (6.9, 34.5) — —
Platelets × 109/L; median (range)‡ 279 (167, 440) — —
*Mann-Whitney U test.
†Fisher Exact test.
‡CRP and differential cell counts were only measured in cases as part of their routine clinical care.
FIGURE 1. Number of children recruited to study and 
number of samples collected from them.
A B
FIGURE 2. A, Circulating plasma endotoxin concentrations 
and (B) urine LMRs in children with noncritical infections 
(cases, red squares) and noninfected controls (green circles). 
The lowest level of endotoxin detection was 0.01 EU/mL. 
Horizontal bars indicate median values. Comparisons were 
made by Mann-Whitney U test; * = P < 0.05.
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classical [70.8% (IQR: 46.8, 78.0) vs. 72.6% (IQR: 58.4, 78.9), 
P = 0.56], intermediate [25.4% (IQR: 16.5, 43.8) vs. 20.2% (IQR: 
16.2, 38.3), P = 0.74], or nonclassical [4.6% (IQR: 3.8 - 10.2) vs. 
5.75% (4.6% - 7.5%), P = 1.00] monocytes. The HLA-DR per-
centage expression was significantly lower in cases compared with 
controls in both the classical [78.8% (IQR: 70.5, 93.0) vs. 95.9% 
(IQR: 92.0, 97.7), respectively; P = 0.001] and intermediate [91.4% 
(IQR: 76.3, 95.9) vs. 97.8% (IQR: 94.9, 98.8), P = 0.004] subpopu-
lations but not the nonclassical (94.3% vs. 95.7%, P = 0.96) sub-
population. CD64 percentage expression on the nonclassical sub-
population was higher in cases than controls (88.9% vs. 67.0%, P = 
0.014), but there was no evidence of difference between groups in 
CD64 expression on the classical (99.9% vs. 99.9%, P = 0.66) and 
intermediate (99.9% vs. 99.6%, P = 0.26) subpopulations (Fig. 3).
Finally, among the neutrophil population (CD66a/c/e+ 
CD16+), the percentage expression of CD64 was significantly 
higher in cases than controls [median 85.2% (IQR: 32.7, 94.7) vs. 
26.9% (IQR: 9.81, 48.2); P = 0.025].
Twenty-four-hour Whole Blood Stimulation
Concentrations of TNF-α, IL-1β and IL-6 measured in 
24-hour whole blood culture supernatants are shown in Figure 4A. 
In unstimulated cultures, levels of IL-1β, but not IL-6 or TNF-α, 
were higher in cases versus controls. Stimulation with either 0.5 
EU/mL of LPS or 0.5 µg/mL of zymosan resulted in significantly 
higher levels of all cytokines compared with cultures with no stim-
ulation. Following stimulation with zymosan, cases versus controls 
produced significantly less TNF-α [median 2342 (IQR: 995, 3961) 
vs. 5130 (IQR: 2400, 6312) pg/mL, respectively; P = 0.031] and 
IL-1β [median 1101 (IQR: 564, 2313) vs. 2604 (IQR: 1339, 3528) 
pg/mL, P = 0.048], but similar IL-6 [median 36,716 (IQR: 18,830, 
51,771) vs. 39,653 (IQR: 28,220, 52,695) pg/mL; P = 0.595]. 
FIGURE 3. Percentage of total monocytes 
(CD66a/c/e− expressing HLA-DR, CD64, 
CD86 and TLR4 in cases and control groups, 
along with heat-maps showing the level 
of expression of each surface marker in 
each group according to the monocyte 
subpopulations defined according to 
CD14/16 expression: classical (CD14++ 
CD16−), intermediate (CD14++ CD16+) and 
nonclassical (CD14+ CD16++). Plots for each 
group shown are concatenated totals of all 
samples in the group. Comparisons made by 
Mann-Whitney U test.
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Following stimulation with LPS, there was no evidence of a differ-
ence in cytokine production between cases and controls (Fig. 4A).
Percentage expression of cell surface markers on monocytes 
following 24 hours of culture is shown in Figure 4B. Because CD64 
was universally expressed on monocytes following stimulation, the 
MFI was used to evaluate the level of CD64 expression on each cell. 
After 24-hour culture without stimulation, CD64 expression levels 
were higher among cases compared with controls [MFI 2570 (IQR: 
1186, 2978) vs. 1591 (IQR: 950, 2173), respectively; P = 0.048; 
Fig. 4B], with no evidence of differences in other markers. Following 
stimulation with LPS, there was no evidence of differences between 
groups in the percentage of monocytes expressing any of the activa-
tion markers (Fig. 4B). Following stimulation with zymosan, the per-
centage of monocytes expressing HLA-DR in cases was significantly 
lower compared with controls [median 89.6% (IQR: 68.5, 97.0) vs. 
99.0% (IQR: 97.4, 99.6), respectively; P = 0.009; Fig. 4B]. As has 
previously been observed,1 unstimulated monocyte HLA-DR expres-
sion across both groups was positively correlated with zymosan-
stimulated TNF-α production (Spearman coefficient = 0.51, 
P = 0.006), and IL-1β (Spearman coefficient = 0.39, P = 0.041).
As expected, following 24-hour stimulation, there was a notice-
able shift in the monocyte subpopulation proportions consistent with 
activation and maturation-specific shifts in CD14 and CD16 expres-
sion.21 The classical population was 13.6% (IQR: 4.8, 43.1) across all 
groups, the intermediate population was 81.3% (IQR: 57.1, 91.8) and 
the nonclassical was 2.6% (IQR: 0.7, 3.9). There was no significant 
difference in these shifts between cases and controls (data not shown).
LOW VERSUS HIGH ENDOTOXIN
To evaluate the impact of circulating endotoxin on monocyte 
immunophenotype, we combined cases and controls and categorized 
children into 2 groups: those with high circulating endotoxin (defined 
as ≥0.1 EU/mL), and those with low circulating endotoxin (<0.1 EU/
mL). This categorization was based on a previous study, in which 0.1 
EU/mL was identified as the upper normal limit in children, using the 
limulus amebocyte lysate assay.32 There were 11 children in the high 
endotoxin group [6 cases and 5 controls; median 0.18 (IQR: 0.11, 
0.39) EU/mL endotoxin] and 17 in the low endotoxin group [3 cases 
and 14 controls; median 0.01 (IQR: 0.01, 0.025) EU/mL endotoxin].
Monocyte Phenotype
In children with high compared with low endotoxin, the per-
centage of monocytes expressing the T-cell costimulatory ligand CD86 
was significantly lower [69.8% (IQR: 58.8, 79.9) vs. 92.4% (IQR: 
79.1, 96.4), P = 0.003; Fig. 5A]. There was no evidence of differences 
between groups in other markers (CD64, HLA-DR and TLR4). The 
lower CD86 expression on total monocytes among higher versus lower 
FIGURE 4. A, Whole blood cytokine production following 24-hour stimulation. B, Percentage of total monocytes (CD66a/c/
e−) expressing surface markers following whole blood culture with (i) no stimulation, (ii) 0.5 EU/mL of LPS or (iii) 0.5 μg/mL 
of zymosan. Comparisons were made by Mann-Whitney U test; * = P<0.05.
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endotoxin was primarily due to lower expression on the classical mono-
cytes [median 65.4% (IQR: 53.1, 78.3) vs. 87.2% (IQR: 76.1, 86.4); 
P = 0.08], and the intermediate monocytes [83.1% (IQR: 72.2, 92.0) vs. 
96.6% (IQR: 84.8, 98.2); P = 0.13], but not on nonclassical monocytes 
[95.5% (IQR: 91.1, 97.9) vs. 96.0% (IQR: 86.3, 96.9); P = 0.41].
Twenty-four-hour Whole Blood Stimulation
When comparing high and low endotoxin groups, there 
was no evidence of differences in elaboration of any cytokine in 
response to zymosan or LPS stimulation (data not shown). After 
stimulation with zymosan, children in the high compared with the 
low endotoxin group expressed significantly less CD64 [MFI 1514 
(IQR: 1170, 1822) vs. 2196 (IQR: 1353, 2857), P = 0.022] and 
CD86 [80.3% (IQR: 57.2, 88.4) vs. 92.2% (IQR: 79.0, 96.0); P = 
0.037] on total monocytes (Fig. 5B), with no evidence of differ-
ences in other markers.
DISCUSSION
In this study, we investigated whether the increased gut per-
meability and immunoparalysis that characterize critical illnesses 
also occur in children with less severe illnesses. We show that chil-
dren with noncritical infections have higher intestinal permeability, 
increased endotoxemia and changes indicative of immunoparalysis, 
with reduced monocyte HLA-DR expression, increased CD64 
expression and reduced IL-1β and TNF-α production upon challenge 
of innate immune cells with the beta-glucan, zymosan. In contrast 
to previous studies, children in this study were not critically unwell. 
Furthermore, we excluded children with any gastrointestinal symp-
toms to ensure that our findings were not due to altered intestinal 
permeability resulting from symptomatic intestinal infections. Endo-
toxemia as a result of increased intestinal permeability is thought 
to be a mediator of immunoparalysis in critically ill patients. In our 
cohort, children with higher circulating endotoxin levels had lower 
basal monocyte CD86 expression and less upregulation of CD64 and 
CD86 upon stimulation, indicative of an impaired capacity to costim-
ulate T-cells and engage with antibody Fc components for enhanced 
specificity and recognition of pathogens. Collectively, these findings 
suggest that children hospitalized for noncritical infections experi-
ence changes in the intestinal barrier and circulating innate immune 
cell function normally associated with more critical illness, which 
could leave them vulnerable to subsequent infections.
The pathogenesis of increased intestinal permeability is likely 
multifactorial. In the context of gastrointestinal infections, there is 
mechanical damage to the epithelium, loss of tight junction integrity 
and villous atrophy arising from local inflammatory processes that 
cause cytokine-dependent changes in the enterocyte cytoskeleton.33–35 
FIGURE 5. A, Surface marker expression on unstimulated monocytes (CD66a/c/e−) in cases and controls subdivided by high 
(>0.1 EU/mL) and low (<0.1 EU/mL) plasma endotoxin levels. B, Monocyte surface markers following 24-hour culture with (i) no 
stimulant, (ii) 0.5 EU/mL of LPS or (iii) 0.5 μg/mL of zymosan. Comparisons were made by Mann-Whitney U test; * = P<0.05.
The Pediatric Infectious Disease Journal • Volume 38, Number 7, July 2019 Gut-immune changes in children with infection
© 2019 The Author(s). Published by Wolters Kluwer Health, Inc. www.pidj.com | 747
In critical illness or sepsis, there is hypoperfusion of the gut, which 
causes epithelial hypoxic injury, acidosis and disarrangement of the 
mucosal cytoskeleton.35 In noncritical infections outside the gut, 
where there is adequate gut perfusion, intestinal permeability is poorly 
described. However, increased intestinal permeability has been dem-
onstrated in murine models of pneumonia,36 and in children with mea-
sles,18 although the presence of diarrhea in 30% of measles cases37 
means the mechanism underlying this observation is difficult to ascer-
tain. This study therefore adds to our understanding of gut function 
during intercurrent illness, because increased intestinal permeability 
was seen in young children with noncritical infections (predominantly 
in the skin, respiratory and urinary tract), and no gastrointestinal symp-
toms. In light of recent observations after experimental intravenous 
administration of LPS to healthy adult donors, which demonstrate a 
dramatic change in circulating monocyte phenotype and function,19 
our data elaborate the association between intestinal permeability and 
monocyte function in children with noncritical illness, raising the pos-
sibility that their innate immune defences may also be compromised in 
ways previously thought to occur only in more severe illness.
Altered intestinal permeability can impair nutrient absorp-
tion, compromise mucosal immune responses15,38 and allow micro-
bial products (such as endotoxin) and viable bacteria to translocate 
to the systemic circulation.36 Microbial translocation during critical 
illness was demonstrated clearly in an adult intensive care study: 
although only 4% of patients had Gram-negative infections, over half 
had endotoxin levels more than 2 standard deviations above healthy 
control levels.5 Although we cannot define the source of endotoxin 
in our study, it is likely that it arose from translocation of bacterial 
products across the intestinal barrier. This is an assumption made 
in other studies,39,40 confirmed in animal models36 and supported by 
the positive correlation between circulating endotoxin and intestinal 
permeability in our study. The weak positive relationship that we 
observed between LMR and circulating endotoxin has been found 
in a previous study,41 although others have found no correlation,42,43 
or a relationship with the percentage lactulose recovery but not the 
LMR,44 albeit in very different populations. This heterogeneity may 
have several explanations: first, there may be a nonlinear relationship 
between permeability and translocation; second, it may reflect the 
fact that lactulose–mannitol testing primarily measures permeability 
of the small intestine, while the greatest Gram-negative bacterial load 
is in the colon45 and third, it may indicate that LPS is not the only 
translocated material that is likely to be immunogenic.
LPS-driven inflammatory responses are implicated in the 
pathogenesis of multiorgan dysfunction in systemic inflammatory 
response syndrome,46 and LPS exposure in monocytes is associated 
with epigenetic reprogramming leading to impaired responses on 
restimulation.3,24 Following LPS exposure in healthy adults, there 
is a rapid reduction in classical monocytes as these cells either die 
or likely mature into intermediate monocytes21 that have enhanced 
antigen presenting and stimulatory ability with increased HLA-
DR47 and CD86 expression.48 The significance of this for our study 
is unclear: HLA-DR and CD64 percentage expression was asso-
ciated with clinical illness rather than higher endotoxemia. This 
may reflect that the endotoxemia measured at the time cases were 
recruited may not reflect previous endotoxemia during their ill-
ness, and once exposed to LPS in vivo effects can last weeks, as 
opposed to the 24 hours seen in vitro models.20
Cases had lower HLA-DR and higher CD64 percentage 
expression than controls, but this was not due to altered numbers of 
intermediate monocytes; rather, cases had reduced HLA-DR expres-
sion on both classical and intermediate monocytes. The consequence 
of this reduced HLA-DR continued following 24 hours of culture with 
another stimulant, zymosan. There was a positive correlation between 
basal monocyte HLA-DR expression and overall TNF-α and IL-1β 
production following zymosan 24-hour culture, and both cytokines 
were significantly reduced in cases. This was not seen in IL-6 that 
is primarily produced by classical monocytes,49 which were signifi-
cantly reduced relative to basal proportions by the end of the 24-hour 
culture. This suggests that any initial changes in circulating cell phe-
notype persist as monocytes mature from the classical to the predomi-
nantly intermediate subtypes in vitro. LPS-stimulated TNF-α pro-
duction was modest and not significantly different between groups. 
This may reflect the fact that at 0.5 EU/mL, the concentration of LPS 
used for stimulation was not substantially higher than that detected 
in plasma of many of the patients. We did not see reversal of some of 
these changes, such as HLA-DR percentage, following culture with 
zymosan, as has previously been seen with beta-glucan stimulation of 
LPS-trained monocytes in vitro.50 Lower HLA-DR and CD64 expres-
sion on monocytes have been associated with increased mortality fol-
lowing sepsis,29 and along with reduced stimulated cytokine produc-
tion, mirror the changes seen in postsepsis immunoparalysis.
In children with higher endotoxemia at the time of venepunc-
ture, monocytes had significantly lower expression of CD86, which 
is a costimulatory molecule required for T-cell priming. Low CD86 
expression on monocytes has been associated with more severe 
sepsis, as demonstrated by an increased Sequential Organ Failure 
Assessment score,51 and increased mortality in mouse models of 
sepsis.52 Monocytes from children with high plasma endotoxin in 
our study exhibited lower expression of CD64 and CD86 following 
stimulation with zymosan compared with monocytes from children 
with lower levels of circulating endotoxin, indicating that exposure 
to circulating LPS alters monocyte responses to subsequent patho-
gen challenge. These findings have been associated with mortality 
and poorer outcomes in children with sepsis.29,52
Limitations of this study include the small sample size, along 
with the heterogeneity of the etiology of the illnesses involved. This 
was intended to be a pilot study investigating responses to systemic 
infection; given some of the diagnostic uncertainty present in diag-
nosis in young children, we were able to show these changes across 
a variety of different types of infections. Because of different health-
seeking behaviors of parents, cases presented at different timepoints 
in their illnesses, so the timing of blood tests was not standardized. 
Although it has been shown that monocyte markers do change over the 
course of an illness,53 in this study, the infected children were different 
to the controls regardless of illness timing. Finally, although the con-
trols in this study did not have a febrile illness, they were still recruited 
from hospital, so would not necessarily be classed as “healthy.”
In summary, we show that children with noncritical infec-
tions and no gastrointestinal symptoms display similar gut and innate 
immune cell alterations as children who have severe sepsis or organ 
failure. In the setting of severe sepsis, these changes are associated 
with increased morbidity and mortality, and susceptibility to future 
infections. Future studies should investigate the molecular triggers of 
these observed changes, how long they persist and the clinical impli-
cations during and after hospitalization. Such studies are warranted 
because children with noncritical infections represent a much larger 
population of children presenting to hospital than children with criti-
cal illness. Whether there is a refractory period of immunoparalysis 
following common childhood infections, and whether interventions 
could improve immune function during this potential window of vul-
nerability, is worthy of further investigation.
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